Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report

Clin Colorectal Cancer. 2021 Jun;20(2):e96-e99. doi: 10.1016/j.clcc.2020.09.004. Epub 2020 Sep 18.
No abstract available

Keywords: Ataxia-telangiectasia mutation; Neoadjuvant therapy; Next-generation sequencing; Pathologic complete response; Platinum chemotherapy.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Ataxia Telangiectasia Mutated Proteins / metabolism
  • Camptothecin / analogs & derivatives*
  • Camptothecin / therapeutic use
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / metabolism
  • Colonic Neoplasms / pathology
  • Drug Therapy, Combination
  • Fluorouracil / therapeutic use
  • Humans
  • Leucovorin / therapeutic use
  • Male
  • Middle Aged
  • Mutation
  • Neoadjuvant Therapy / methods*
  • Organoplatinum Compounds / therapeutic use
  • Panitumumab / therapeutic use*
  • Treatment Outcome

Substances

  • Organoplatinum Compounds
  • Panitumumab
  • ATM protein, human
  • Ataxia Telangiectasia Mutated Proteins
  • Leucovorin
  • Fluorouracil
  • Camptothecin

Supplementary concepts

  • FOLFOXIRI protocol